Idorsia (XSWX:IDIA) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:IDIA Idorsia Ltd XSWX:IDIA
48 GF Score
Price CHF5.92
GF Value CHF2.88
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Idorsia Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

XSWX:IDIA
48GF Score
Idorsia Ltd XSWX:IDIA
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Idorsia (XSWX:IDIA) Overvalued in 2026?

Based on GuruFocus' analysis, Idorsia stock appears to be overvalued. The current stock price of CHF5.92 is trading 105.4% above its estimated GF Value™ of CHF2.88. GuruFocus considers Idorsia to be Significantly Overvalued.

Key valuation signals for XSWX:IDIA:

  • Cash Payments:
  • GF Value™: CHF2.88 vs. price of CHF5.92 (105.4% above fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Idorsia Business Description

Address Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score

Get the complete analysis for XSWX:IDIA

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF5.92
Price
CHF2.88
GF Value